T Cell News and Research

Latest T Cell News and Research

Northwestern researchers continue to tackle every facet of COVID-19 pandemic

As the COVID-19 pandemic nears the two-year mark, Northwestern Medicine scientists continue to tackle every facet of the disease, from investigating coronavirus vaccines' potential for providing immunity against similar coronaviruses to developing novel rapid antigen-based tests and examining disparities in COVID-19 case and mortality rates in Chicago.

30 Nov 2021

Omicron and other coronavirus variants: What you need to know

Americans, already weary of a pandemic nearly two years long, were dealt a new blow during the long Thanksgiving weekend: the announcement that a new coronavirus variant had emerged.

30 Nov 2021

Cytomegalovirus herpesvirus can accelerate the decline of the immune system, study finds

A research team at the University of Córdoba is studying the alterations that occur in the immune system's T lymphocytes with respect to age and in relation to the cytomegalovirus herpesvirus.

29 Nov 2021

Safety and immunogenicity of COVID-19 peptide vaccine

In a study published in Nature, researchers from University Hospital Tübingen have been investigating the results from a Phase I trial for a new vaccine against SARS-CoV-2 variants.

25 Nov 2021

SARS-CoV-2 reinfection and the natural immune response

Researchers review available literature on immunity and SARS-CoV-2 infection to elucidate mechanisms behind SARS-CoV-2 immunity and reinfections.

24 Nov 2021

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

24 Nov 2021

An assessment of potential epitopes in SARS-CoV-2 structural proteins

Researchers utilized multiple bioinformatics resources to identify potent T- and B-cell epitopes of four SARS-CoV-2 structural proteins.

24 Nov 2021

Finding potential biomarkers to predict response to immunotherapy in nonhypermutated cancers

Scientists have discovered a potential biomarker that could more accurately identify which patients with non-hypermutated cancers will respond to specialized immunotherapy drugs called immune checkpoint inhibitors, according to findings published in Science Translational Medicine.

24 Nov 2021

GABA secreted by B-cells blunts the body's cytotoxic T-cell-based response to tumors

A group of scientists led by researchers from the RIKEN Center for Integrative Medical Sciences have discovered that B-cells, a type of immune cell, secrete the neurotransmitter GABA, and also found that the GABA secreted by the B-cells promoted the emergence of anti-inflammatory macrophages, blunting the body's cytotoxic T-cell-based response to tumors.

21 Nov 2021

Severe COVID-19 patients have significantly higher NK and T cell frequency

A new study published in the open-access journal Cells aimed to clarify the role of NK and T cell subsets in SARS-CoV-2 infection in hospitalized COVID-19 patients to unravel their potential association with disease severity.

18 Nov 2021

Short-term severe calorie restriction safe, feasible, and well tolerated by cancer patients

A diet involving short-term, severe calorie restriction was safe, feasible, and resulted in a decrease of blood glucose and growth factor concentration, reduction in peripheral blood immunosuppressive cells, and enhanced intratumor T-cell infiltration in cancer patients receiving standard-of-care therapy, according to the results of a clinical trial.

18 Nov 2021

Phantosmia, parosmia, and dysgeusia in COVID-19 patients

A team of researchers investigated qualitative aspects of olfactory and gustatory symptoms such as phantosmia, parosmia, and dysgeusia and their possible co-relation with the adaptive immune system.

17 Nov 2021

Deficient spike-specific T cell responses and inability to neutralize SARS-CoV-2 variants 12 month post-infection

Researchers conducted a comprehensive, longitudinal, long-term immune study, including functional assays to assess immune fitness against antigenically different VoC. The study is currently available on the preprint server medRxiv* while awaiting peer review.

15 Nov 2021

Researchers develop a highly efficient method to generate immune cells for cancer therapies

A Ludwig Cancer Research study has devised a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens - small fragments of randomly mutated proteins that are typically unique to a patient's cancer - and destroy the tumors that express them.

15 Nov 2021

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

Previous
1
...
45
46
47
48
49
50
51
...
2905
Next

T Cell News and Research

Latest T Cell News and Research

Northwestern researchers continue to tackle every facet of COVID-19 pandemic

Omicron and other coronavirus variants: What you need to know

Cytomegalovirus herpesvirus can accelerate the decline of the immune system, study finds

Safety and immunogenicity of COVID-19 peptide vaccine

SARS-CoV-2 reinfection and the natural immune response

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

An assessment of potential epitopes in SARS-CoV-2 structural proteins

Finding potential biomarkers to predict response to immunotherapy in nonhypermutated cancers

GABA secreted by B-cells blunts the body's cytotoxic T-cell-based response to tumors

Severe COVID-19 patients have significantly higher NK and T cell frequency

Short-term severe calorie restriction safe, feasible, and well tolerated by cancer patients

Phantosmia, parosmia, and dysgeusia in COVID-19 patients

Deficient spike-specific T cell responses and inability to neutralize SARS-CoV-2 variants 12 month post-infection

Researchers develop a highly efficient method to generate immune cells for cancer therapies

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

Study identifies a host factor that reflects different levels of inflammation within mild COVID-19 cases

Mycobacterium tuberculosis may induce resistance to secondary SARS-CoV-2 infection

Increased risk of breakthrough SARS-CoV-2 infection with ChAdOx1 compared to BNT162b2 vaccine

Study assesses whether medicinal mushrooms and Chinese herbs can help treat COVID-19

SARS-CoV-2 self-amplifying mRNA vaccine demonstrates cellular and humoral immune responses

Immunology eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in